Analyst Reco. Guardant Health, Inc.

Equities

GH

US40131M1099

Medical Equipment, Supplies & Distribution

Real-time Estimate Cboe BZX Other stock markets 17:33:07 17/02/2026 GMT			5-day change	1st Jan Change
107.10 ^USD	+2.14%		+1.71%	+4.59%

02-02	Guardant Health, Inc. Announces Publication of the Largest Study to Date Evaluating Circulating Tumors forMRD Detection in Patients with Rescted Stage III Colon Cancer After Surgery and Before Adjuvant Chemotherapy	CI
01-30	UBS Adjusts Price Target on Guardant Health to $175 From $110, Maintains Buy Rating	MT

Analyst Reco.

12:39pm	Baird Initiates Guardant Health at Outperform With $120 Price Target	MT
01-30	UBS Adjusts Price Target on Guardant Health to $175 From $110, Maintains Buy Rating	MT
12-02	Morgan Stanley Raises Price Target on Guardant Health to $130 From $105, Keeps Overweight Rating	MT
30/10/25	UBS Adjusts Guardant Health Price Target to $110 From $80, Maintains Buy Rating	MT
29/09/25	Guardant Health Says US FDA Approves its Blood Test as Companion Diagnostic for Eli Lilly's Inluriyo	MT
25/09/25	Guardant Health Shares Rise After Wolfe Upgrade	MT
25/09/25	UBS Adjusts Guardant Health Price Target to $80 From $70, Maintains Buy Rating	MT
25/09/25	Wolfe Research Upgrades Guardant Health to Outperform From Peer Perform, Price Target is $75	MT
30/07/25	Guardant Health Q2 revenue beats estimates	RE
02/05/25	Morgan Stanley Raises Price Target on Guardant Health to $60 From $52, Keeps Overweight Rating	MT
01/05/25	UBS Adjusts Guardant Health Price Target to $70 From $65, Maintains Buy Rating	MT
14/04/25	BofA Securities Raises Price Target on Guardant Health to $60 From $56, Keeps Buy Rating	MT
10/04/25	Mizuho Initiates Guardant Health at Outperform	MT
06/03/25	Guardant Health Base Business in 'Fundamentally Good Shape,' Morgan Stanley Says	MT
05/03/25	Morgan Stanley Adjusts Price Target on Guardant Health to $52 From $42, Keeps Overweight Rating	MT
21/02/25	UBS Adjusts Guardant Health Price Target to $65 From $40, Maintains Buy Rating	MT
23/01/25	Barclays Initiates Guardant Health at Overweight	MT
26/08/24	Nephron Research Downgrades Guardant Health to Sell From Hold, $23 Price Target	MT
21/08/24	UBS Raises Price Target on Guardant Health to $40 From $32, Maintains Buy Rating	MT
28/06/24	Guggenheim Upgrades Guardant Health to Buy From Neutral, Price Target at $36	MT
04/06/24	Canaccord Genuity Adjusts Price Target on Guardant Health to $38 From $30, Maintains Buy Rating	MT
03/06/24	Jefferies Initiates Guardant Health at Buy Rating With $32 Price Target	MT
29/04/24	Canaccord Genuity Adjusts Price Target on Guardant Health to $30 From $45, Maintains Buy Rating	MT
15/04/24	Goldman Sachs Adjusts Guardant Health Price Target to $28 From $32, Maintains Buy Rating	MT
26/02/24	Piper Sandler Cuts Price Target on Guardant Health to $30 From $40, Maintains Overweight Rating	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Analyst Reco. Guardant Health, Inc.

Equities

GH

US40131M1099

Medical Equipment, Supplies & Distribution

Analyst Reco.

Filters